Alma Therapeutics

Executive Summary

Alma Therapeutics is an Israeli biotech pioneering a novel oral delivery platform that converts injectable biologics, including peptides, enzymes, and monoclonal antibodies, into patient-friendly capsules. The technology aims to eliminate painful infusions and frequent injections, significantly improving patient compliance and reducing healthcare costs for chronic diseases such as diabetes, autoimmune disorders, and neurodegenerative conditions. Founded in 2020 and headquartered in Tel Aviv, the company operates at the preclinical stage, leveraging proprietary formulations to protect biologics through the gastrointestinal tract and enable systemic absorption. Its approach addresses a major unmet need in drug delivery, potentially unlocking larger markets for existing biologics and enabling new oral therapies. Despite being in preclinical development, Alma Therapeutics has demonstrated proof-of-concept in animal models for several classes of biologics. The platform's versatility could attract partnerships with pharmaceutical companies seeking to reformulate their injectable assets or develop oral versions of biologic drugs. The company is actively advancing toward IND-enabling studies and expects to initiate first-in-human trials within the next 12-18 months. Given the strong market demand for oral biologics, the experienced management team, and the significant clinical and commercial upside, Alma Therapeutics represents a compelling early-stage opportunity in the biotech space.

Upcoming Catalysts (preview)

• Q4 2026Preclinical PK/PD Data Readout Across Multiple Biologic Classes60% success
• Q2 2027Strategic Partnership with Major Pharma for Co-Development or Licensing50% success
• Q3 2026Series B Financing to Fund IND-Enabling Studies40% success